QTTBQ32 Bio Inc.

Patients treated with bempikibart for 36 weeks saw a 35% average reduction in scalp hair loss severity, the company said.

Q32 Bio Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants Q32 Bio Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants PR Newswire WALTHAM, Mass., July 13, 2026 WALTHAM, Mass., July 13, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB), ("Q32 Bio") a...

Gainers Agenus (NASDAQ:AGEN) shares increased by 95.8% to $6.56 during Monday's regular session. The market value of their outstanding shares is at $139.5 million. Q32 Bio (NASDAQ:QTTB) stock rose 81.08% to $20.3.read more...

From a transformational merger and corporate restructuring at Twin Vee PowerCats, to encouraging Phase 2 clinical data from Q32 Bio, major oncology financing by Agenus, government-backed AI development at Pulsenmore, shareholder returns from LogProstyle, and new third-party testing validating Xeriant's advanced construction materials, this week's developments demonstrate the diverse catalysts capable of reshaping small-cap growth stories. $VEEE, $XERI, $PLSM, $LGPS, $QTTB, $AGEN

Q32 Bio reported positive Phase 2a data for bempikibart in severe alopecia areata, showing hair regrowth and favorable safety.read more...

Gainers Pulsenmore (NASDAQ:PLSM) shares increased by 171.2% to $10.47 during Monday's pre-market session. The company's market cap stands at $25.1 million. Q32 Bio (NASDAQ:QTTB) stock rose 65.92% to $18.6. Theread more...

Positive clinical data can rapidly change the outlook for an emerging biotechnology company, and Q32 Bio (NASDAQ:QTTB) may have delivered one of its most important milestones to date. The clinical-stage biotech announced encouraging 36-week topline results from Part B of its Phase 2a SIGNAL-AA trial evaluating bempikibart for patients with severe or very severe alopecia areata—a disease affecting roughly 700,000 people in the United States with limited treatment options.

Q32 Bio Announces Positive 36-Week Topline Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata Q32 Bio Announces Positive 36-Week Topline Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata PR Newswire WALTHAM, Mass., July 13, 2026...

Gainers: Q32 Bio up 29.6%, Mint up 75.8%, Fast Track up 58.2%, eLong up 33.4%, Sobr Safe up 29.2%, Eshallgo up 20.3%, Curis up 10.9%, Sky Quarry up 10.6%, Accuray up 9.5%, Bitzero up 5.5%. Losers: Global Mofy down 25.3%, Jiuzi down 22.1%, Julong down 21.4%, Haoxi down 20.4%, Sadot down 20.4%.read...